In vitro activity of eravacycline and comparator antimicrobials against 143 recent strains of Bacteroides and Parabacteroides species

Anaerobe. 2018 Aug;52:122-124. doi: 10.1016/j.anaerobe.2018.06.016. Epub 2018 Jul 4.


Eravacycline, a novel fluorocycline antibiotic, has been evaluated against complicated mixed aerobic/anaerobic intra-abdominal infections but scant supporting in vitro data against anaerobes has been published. We found that eravacycline had good anaerobic in vitro activity with MICs of 4 μg/ml or less against all Bacteroides and Parabacteroides strains tested, except for two B. ovatus strains that had MICs of 8 μg/ml and one strain that had an MIC of 16 μg/ml. Eravacycline was four-to-eight fold more active than tigecycline.

Keywords: Anaerobes; Bacteroides fragilis; Eravacycline; Tigecycline.

Publication types

  • Comparative Study

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • Bacteroides / drug effects*
  • Bacteroides / growth & development
  • Bacteroidetes / drug effects*
  • Bacteroidetes / growth & development
  • Humans
  • Intraabdominal Infections / microbiology*
  • Microbial Sensitivity Tests
  • Minocycline / analogs & derivatives
  • Minocycline / pharmacology
  • Tetracyclines / pharmacology*
  • Tigecycline


  • Anti-Bacterial Agents
  • Tetracyclines
  • eravacycline
  • Tigecycline
  • Minocycline